1. Home
  2. LXRX vs DIAX Comparison

LXRX vs DIAX Comparison

Compare LXRX & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LXRX

Lexicon Pharmaceuticals Inc.

HOLD

Current Price

$1.68

Market Cap

547.4M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest

DIAX

Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest

HOLD

Current Price

$14.51

Market Cap

561.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXRX
DIAX
Founded
1995
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
547.4M
561.9M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
LXRX
DIAX
Price
$1.68
$14.51
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.15
N/A
AVG Volume (30 Days)
2.3M
130.1K
Earning Date
06-08-2026
01-01-0001
Dividend Yield
N/A
7.93%
EPS Growth
77.78
N/A
EPS
N/A
N/A
Revenue
$49,803,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$22.16
N/A
P/E Ratio
N/A
N/A
Revenue Growth
60.24
N/A
52 Week Low
$0.32
$12.42
52 Week High
$1.83
$15.85

Technical Indicators

Market Signals
Indicator
LXRX
DIAX
Relative Strength Index (RSI) 62.33 24.14
Support Level $1.08 $14.49
Resistance Level $1.83 $14.97
Average True Range (ATR) 0.13 0.21
MACD 0.01 -0.08
Stochastic Oscillator 71.62 2.20

Price Performance

Historical Comparison
LXRX
DIAX

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest

Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.

Share on Social Networks: